Rhinitis, Allergic, Perennial Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years With Seasonal Allergic Rhinitis (SAR)
| Verified date | September 2016 |
| Source | GlaxoSmithKline |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
The purpose of this study is to determine if the investigational drug is effective and safe in children with seasonal allergic rhinitis.
| Status | Completed |
| Enrollment | 576 |
| Est. completion date | November 2005 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 2 Years to 12 Years |
| Eligibility |
Inclusion criteria: - Diagnosis of seasonal allergic rhinitis. - Adequate exposure to seasonal (Spring/Summer) allergen prevalent to the geographic area. Exclusion criteria: - Have significant concomitant medical conditions. - Use of corticosteroids, other allergy meds during the study. - Have abnormal ECG or laboratory abnormality. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | GSK Investigational Site | Altoona | Pennsylvania |
| United States | GSK Investigational Site | Baltimore | Maryland |
| United States | GSK Investigational Site | Bethesda | Maryland |
| United States | GSK Investigational Site | Brockton | Massachusetts |
| United States | GSK Investigational Site | Canton | Ohio |
| United States | GSK Investigational Site | Centennial | Colorado |
| United States | GSK Investigational Site | Charleston | South Carolina |
| United States | GSK Investigational Site | Cincinnati | Ohio |
| United States | GSK Investigational Site | Costa Mesa | California |
| United States | GSK Investigational Site | Cranberry Township | Pennsylvania |
| United States | GSK Investigational Site | Cudahy | California |
| United States | GSK Investigational Site | Dallas | Texas |
| United States | GSK Investigational Site | Dallas | Texas |
| United States | GSK Investigational Site | Denver | Colorado |
| United States | GSK Investigational Site | Denver | Colorado |
| United States | GSK Investigational Site | Durham | North Carolina |
| United States | GSK Investigational Site | El Paso | Texas |
| United States | GSK Investigational Site | El Paso | Texas |
| United States | GSK Investigational Site | Englewood | Colorado |
| United States | GSK Investigational Site | Fort Collins | Colorado |
| United States | GSK Investigational Site | Gainesville | Georgia |
| United States | GSK Investigational Site | Greenfield | Wisconsin |
| United States | GSK Investigational Site | Hackensack | New Jersey |
| United States | GSK Investigational Site | Huntington Beach | California |
| United States | GSK Investigational Site | Indianapolis | Indiana |
| United States | GSK Investigational Site | Ithaca | New York |
| United States | GSK Investigational Site | Jackson | Mississippi |
| United States | GSK Investigational Site | Kansas City | Missouri |
| United States | GSK Investigational Site | Knoxville | Tennessee |
| United States | GSK Investigational Site | Lake Oswego | Oregon |
| United States | GSK Investigational Site | Lakewood | Colorado |
| United States | GSK Investigational Site | Lawrenceville | Georgia |
| United States | GSK Investigational Site | Lilburn | Georgia |
| United States | GSK Investigational Site | Little Rock | Arkansas |
| United States | GSK Investigational Site | Long Beach | California |
| United States | GSK Investigational Site | Long Beach | California |
| United States | GSK Investigational Site | Madison | Wisconsin |
| United States | GSK Investigational Site | Metairie | Louisiana |
| United States | GSK Investigational Site | Miami | Florida |
| United States | GSK Investigational Site | Mineola | New York |
| United States | GSK Investigational Site | Mission Viejo | California |
| United States | GSK Investigational Site | Nashville | Tennessee |
| United States | GSK Investigational Site | North Andover | Massachusetts |
| United States | GSK Investigational Site | North Dartmouth | Massachusetts |
| United States | GSK Investigational Site | Ocean | New Jersey |
| United States | GSK Investigational Site | Oklahoma City | Oklahoma |
| United States | GSK Investigational Site | Omaha | Nebraska |
| United States | GSK Investigational Site | Orange | California |
| United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
| United States | GSK Investigational Site | Raleigh | North Carolina |
| United States | GSK Investigational Site | Richland | Michigan |
| United States | GSK Investigational Site | Riverside | California |
| United States | GSK Investigational Site | Rolla | Missouri |
| United States | GSK Investigational Site | San Diego | California |
| United States | GSK Investigational Site | Scottsdale | Arizona |
| United States | GSK Investigational Site | Shreveport | Louisiana |
| United States | GSK Investigational Site | Springfield | Massachusetts |
| United States | GSK Investigational Site | Stockbridge | Georgia |
| United States | GSK Investigational Site | Tampa | Florida |
| United States | GSK Investigational Site | Topeka | Kansas |
| United States | GSK Investigational Site | Utica | New York |
| United States | GSK Investigational Site | Walnut Creek | California |
| United States | GSK Investigational Site | Warrensburg | Missouri |
| United States | GSK Investigational Site | Woodstock | Georgia |
| United States | GSK Investigational Site | Ypsilanti | Michigan |
| Lead Sponsor | Collaborator |
|---|---|
| GlaxoSmithKline |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Improvement in daily, reflective total nasal symptom scores after 2 weeks of treatment in subjects ages 6 to <12 years. | |||
| Secondary | Improvement in AM, pre-dose, instantaneous total nasal symptom scores after 2 weeks of treatment, overall evaluation of response to therapy after 2 weeks of treatment for subjects ages 6 to <12 years. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02443805 -
Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR
|
Phase 3 | |
| Completed |
NCT01231464 -
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT00224523 -
Long Term Safety Of GW685698X Via Nasal Biopsy
|
Phase 3 | |
| Completed |
NCT00232518 -
Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis
|
N/A | |
| Completed |
NCT00658918 -
To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)
|
Phase 3 | |
| Completed |
NCT00404586 -
Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber
|
Phase 1 | |
| Withdrawn |
NCT02988778 -
Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT00988247 -
Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT01644617 -
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
|
Phase 2 | |
| Completed |
NCT01678807 -
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
|
Phase 1 | |
| Completed |
NCT01216384 -
Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers
|
Phase 1 | |
| Completed |
NCT00848965 -
A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber
|
Phase 4 | |
| Completed |
NCT00092118 -
The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)
|
Phase 3 | |
| Completed |
NCT00839189 -
Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults
|
Phase 1 | |
| Completed |
NCT00570492 -
Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.
|
Phase 4 | |
| Completed |
NCT00806754 -
Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)
|
Phase 4 | |
| Recruiting |
NCT00153595 -
EWO1 in Persistent Allergic Rhinitis Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT00132925 -
An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT02498509 -
Clinical Trial to Evaluate the Efficacy and Safety of CKD-342
|
Phase 3 | |
| Completed |
NCT01134705 -
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
|
Phase 3 |